We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03536559
Recruitment Status : Terminated (COVID-19 related enrollment challenges.)
First Posted : May 24, 2018
Last Update Posted : August 12, 2022
Clene Australia Pty Ltd
Information provided by (Responsible Party):
Clene Nanomedicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 27, 2022
Actual Study Completion Date : July 12, 2022